Drug Trial Radar · NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
609
Actual
Start
Jun 3, 2025
Primary completion
Mar 1, 2027
Study completion Oct 17, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jun 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
Conditions
- Obesity
Interventions
CagriSema (Cagrilintide B and Semaglutide I)Drug
CagriSema (Cagrilintide B and Semaglutide I) will be administered subcutaneously using DV3384 pen-injector.
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Drug
Placebo matched to Cagrilintide B and placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to week 80
Locations
47 sites in 1 country. Site status is shown where the registry gives one.
FDRC
Costa Mesa, California
Linda Vista Health Care Ctr
San Diego, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Northeast Research Institute
Fleming Island, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
South Broward Research LLC
Miramar, Florida
Florida Inst For Clin Res LLC
Orlando, Florida
Oviedo Medical Research, LLC
Oviedo, Florida
Center for Diab,Obes & Metab
Pembroke Pines, Florida
Hope Clin Res & Wellness
Conyers, Georgia
Endocrine Research Solutions
Roswell, Georgia
Great Lakes Clinical Trials
Chicago, Illinois
Endeavor Health
Skokie, Illinois
Evanston Premier Hlthcr Res
Skokie, Illinois
Midwest Inst For Clin Res
Indianapolis, Indiana
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Northern Pines Hlth Ctr, PC
Buckley, Michigan
StudyMetrix Research LLC
City of Saint Peters, Missouri
Amicis Centers of Clinical Research
St Louis, Missouri
Mercury Str Med Grp, PLLC
Butte, Montana
Southgate Medical Group, LLP
West Seneca, New York
Great Lakes Medical Research
Westfield, New York
University of North Carolina
Chapel Hill, North Carolina
Medication Mgmnt, LLC_Grnsboro
Greensboro, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Accellacare_NC
Raleigh, North Carolina
Piedmont Healthcare/Research
Statesville, North Carolina
Accellacare
Wilmington, North Carolina
New Venture Medical Research
Wadsworth, Ohio
Lynn Institute of Norman
Norman, Oklahoma
Clinical Res Collaborative
Cumberland, Rhode Island
Coastal Carolina Res Ctr
North Charleston, South Carolina
Hillcrest Clinical Research
Simpsonville, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
Holston Medical Group
Kingsport, Tennessee
Clinical Research Associates
Nashville, Tennessee
Amarillo Medical Specialists
Amarillo, Texas
Velocity Clin Res, Dallas
Dallas, Texas
PlanIt Research, PLLC
Houston, Texas
Radiance Clinical Research
Lampasas, Texas
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.